PEPHORMIA
← All goals Information bank

Recovery & repair

Tissue, tendon, wound and post-procedure — big animal literature, thin human data.

BPC-157 · TB-500 · GHK-Cu

Our writeups

0

Graded dossiers for recovery & repair are in production. The primary papers and regulatory reads are below now — our writeups land on top as they publish.

Get them first →

Primary papers

2
Emerging use of BPC-157 — a systematic review
Vasireddi N, et al. HSS Journal 2025 (35 preclinical : 1 uncontrolled human)
Doesn't show: No completed controlled human efficacy trials; WADA-prohibited.
Weak↗
Thymosin β4 / TB-500 in tissue repair
Reviews of the fragment vs full-length Tβ4
Doesn't show: Human trials are on full-length Tβ4, not the TB-500 fragment.
Weak↗

Regulatory

2
FDA Pharmacy Compounding Advisory Committee — 7-peptide review
FDA · docket FDA-2025-N-6895 · 23–24 Jul 2026
Advisory vote on the 503A compounding list — not approval, not consumer legalisation.
official↗
TGA — scheduling of peptides in Australia (Poisons Standard)
Therapeutic Goods Administration (AU)
Most listed peptides are prescription / scheduled in Australia.
official↗

Educational purpose only. PEPHORMIA aggregates and grades published scientific literature. Nothing here is medical advice, diagnosis, or treatment, and nothing here is a recommendation to obtain, dose, or use any compound. We do not sell, supply, or facilitate access to prescription medicines or injectable peptides. Products offered are cosmetic-grade topical formulations described by appearance only. Peptide and hormone use carries real risks — consult a qualified healthcare professional before any decision. Statements have not been evaluated by the TGA or FDA.